linkedin post 2013-04-08 05:26:25

ONE THIRD OF EU PATIENTS NEEDING A RARE DISEASE DRUG WILL HAVE DIFFICULTY getting the drug paid for as the EU tightens reimbursement on costly drugs. Different countries have different criteria on this controversial issue. Determining what is a ‘fair’ return for an innovator appears to be a consideration for some regulators. Without incentives, biopharma companies would not go after diseases with small populations. Patient groups are understandably concerned when drug access is limited, and a number of them have actually paid for R&D and clinical trials for these drugs (500 M USD/yr).

http://mobile.bloomberg.com/news/2013-04-07/orphan-drug-prices-under-siege-in-austerity-minded-europe.html

View in LinkedIn